Clinical Trial Update: Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a two-step anti-thymocyte globulin (ATG) regimen to prevent acute graft-versus-host disease after myeloablative allogeneic stem cell tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Anti-thymocyte globulin (ATG) (anti-thymocyte globulin)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: GVHD,Acute, Acute Leukemia | Phase 2 | Status: RECRUITING